Back to search results

Contrast Enhanced Super Resolution (CESR) Imaging for Breast, Kidney, and Liver Lesions

This study is looking at a new way to use ultrasound imaging, called Contrast Enhanced Super Resolution (CESR) imaging, to get clearer pictures of lesions (abnormal areas) in the breast, kidney, and liver. Researchers will use a special ultrasound machine along with a contrast agent called perflutren lipid, which is given through an IV (into a vein). The goal is to see how well CESR imaging can find and identify these lesions compared to standard methods. You might be able to join if you are an adult, have had a diagnostic ultrasound at the University of North Carolina, are scheduled for a biopsy, and have a lesion that can be seen on ultrasound. The study aims to enroll 40 participants.

Study design
This is a single-center study involving 40 participants, including 10 healthy volunteers and 30 patients with lesions in the breast, liver, or kidney.
What's involved
You would receive the contrast agent perflutren lipid intravenously and undergo CESR imaging using a research ultrasound scanner. You would be monitored for 15 minutes after the contrast agent is given.
Compensation
Not stated in the trial record.
Follow-up
Your imaging results will be evaluated up to 2 months after your biopsy date.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07225114

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging

Recruiting
PHASE2Ages 18+InterventionalDiagnostic
UNC Lineberger Comprehensive Cancer Center
~40 participants
Updated 2026-06-08 on ClinicalTrials.gov
What's tested:contrast agent perflutren lipidUltrasound Imaging

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sensitivity of Contrast Enhanced Super-Resolution (CESR) breast imaging
Measured over Biopsy date (Up to 2 months)
+5 more outcomes measured

Conditions

Breast Cancer
Kidney Neoplasms
Liver Neoplasms

Explore related trials

Breast CarcinomaHealthy VolunteersKidney NeoplasmNeoplasm of liver

Where it's being run

1 sites across 1 states
North Carolina1

Study leadership

  • Yueh Lee, MD · PRINCIPAL_INVESTIGATOR · UNC Lineberger Comprehensive Cancer Center

Who to contact

Desma Jones
[email protected]
(919) 843-9463
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults ≥18 years old
Patient had a diagnostic ultrasound study performed at University of North Carolina
Scheduled for a biopsy
Lesion visualized on ultrasound
Able to provide informed consent
Negative urine pregnancy test in women of child-bearing potential

Exclusion

Institutionalized subject (prisoner or nursing home patient)
Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease (COPD)
Known hypersensitivity to sulfur hexafluoride or to any component of perflutren lipid (Definity®)
Active cardiac disease including any of the following
Severe congestive heart failure (class IV in accordance with the classification of the New York Heart Association)
Unstable angina.
Severe arrhythmia (i.e., ventricular tachycardia, flutter fibrillation; ventricular premature complexes occurring close to the preceding T-wave, multifocal complexes).
Myocardial infarction within 14 days prior to the date of proposed Definity® administration.
Pulmonary hypertension
Cardiac shunts

What this trial measures

  • Sensitivity of Contrast Enhanced Super-Resolution (CESR) breast imagingBiopsy date (Up to 2 months)

    Sensitivity of Contrast Enhanced Super-Resolution (CESR) breast imaging will be evaluated by comparing image analyses to the pathological results for these lesions. Sensitivity will be defined as the proportion of lesions detected by CESR to be positive among lesions confirmed as positive by pathological results.

  • Specificity of Contrast Enhanced Super-Resolution (CESR) breast imagingBiopsy date (Up to 2 months)

    Specificity of Contrast Enhanced Super-Resolution (CESR) breast imaging will be evaluated by comparing image analyses to the pathological results for these lesions. Specificity will be defined as the proportion of lesions detected by CESR to be negative among lesions confirmed as negative by pathological results.

  • Sensitivity of Contrast Enhanced Super-Resolution (CESR) kidney imagingBiopsy date (Up to 2 months)

    Sensitivity of Contrast Enhanced Super-Resolution (CESR) kidney imaging will be evaluated by comparing image analyses to the pathological results for these lesions. Sensitivity will be defined as the proportion of lesions detected by CESR to be positive among lesions confirmed as positive by pathological results.

  • Specificity of Contrast Enhanced Super-Resolution (CESR) kidney imagingBiopsy date (Up to 2 months)

    Specificity of Contrast Enhanced Super-Resolution (CESR) kidney imaging will be evaluated by comparing image analyses to the pathological results for these lesions. Specificity will be defined as the proportion of lesions detected by CESR to be negative among lesions confirmed as negative by pathological results.

  • Sensitivity of Contrast Enhanced Super-Resolution (CESR) liver imagingBiopsy date (Up to 2 months)

    Sensitivity of Contrast Enhanced Super-Resolution (CESR) liver imaging will be evaluated by comparing image analyses to the pathological results for these lesions. Sensitivity will be defined as the proportion of lesions detected by CESR to be positive among lesions confirmed as positive by pathological results.

  • Specificity of Contrast Enhanced Super-Resolution (CESR) liver imagingBiopsy date (Up to 2 months)

    Specificity of Contrast Enhanced Super-Resolution (CESR) liver imaging will be evaluated by comparing image analyses to the pathological results for these lesions. Specificity will be defined as the proportion of lesions detected by CESR to be negative among lesions confirmed as negative by pathological results.